News
ARVN
32.37
+2.44%
0.77
Arvinas (ARVN) Shares Cross Below 200 DMA
NASDAQ · 2d ago
ARVINAS APPOINTS RANDY TEEL, PH.D., AS CHIEF BUSINESS OFFICER
Reuters · 3d ago
Press Release: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Arvinas, Inc. Appoints Randy Teel, Ph.D., as Chief Business Officer. Dr. Teel currently serves as Arvinas' interim Chief Financial Officer and Treasurer. The company is a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation.
Dow Jones · 3d ago
UPDATE 4-Novartis raises guidance after beating Q1 expectations
Novartis raises full-year guidance on wider use of psoriasis and arthritis drug Cosentyx. Swiss drugmaker beats Q1 expectations with revenue up 10% to $11.83 billion. Former boss of Bristol Myers Squibb to become Novartis chairman year.
Reuters · 5d ago
Weekly Report: what happened at ARVN last week (0415-0419)?
Weekly Report · 5d ago
Multiple Insiders Sold Arvinas Shares Presenting Weak Signs For Investors
Arvinas, Inc. Insiders sold US$485k worth of shares in the last year. The biggest insider sale was by John Houston for US$244k. In the last 12 months, Arvinas insiders didn't buy any shares. The company has a 1.9% of the company. But the company has seen significant insider selling over the last three months. It's important to keep in mind Arvin as an company to watch.
Simply Wall St · 04/18 11:11
Analysts’ Top Healthcare Picks: Quanterix (QTRX), Intuitive Surgical (ISRG)
TipRanks · 04/16 06:40
Arvinas Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/15 11:38
Arvinas Price Target Cut to $87.00/Share From $90.00 by HC Wainwright & Co.
Dow Jones · 04/15 11:38
Weekly Report: what happened at ARVN last week (0408-0412)?
Weekly Report · 04/15 09:05
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
NASDAQ · 04/12 17:55
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
TipRanks · 04/12 12:29
Arvinas Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/12 11:25
HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $87
Benzinga · 04/12 11:15
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
TipRanks · 04/12 11:10
ARVINAS, INC. <ARVN.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $87 FROM $90
Reuters · 04/12 10:53
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
Arvinas and Novartis partnering on prostate cancer protein degrader is a win-win situation for both parties. Arvinas's shares are up more than 75% since November 2023. The biotech's lead asset, vepdegestrant, is being developed in partnership with Pfizer for breast cancer studies.
Seeking Alpha · 04/11 19:50
BUZZ-U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
The Dow Jones Industrial Average was up 0.02% on Thursday. The benchmark S&P 500 and the Dow were muted as long-dated Treasury yields remained elevated. Rent the Runway, Lumen Technologies, Enliven Therapeutics were among the top stocks on the NYSE.
Reuters · 04/11 18:05
Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential
TipRanks · 04/11 17:05
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
The benchmark S&P 500 and the Nasdaq gained on Thursday. Producer prices data soothed investor jitters about sticky inflation. The Dow Jones Industrial Average was down 0.36% in the morning. Constellation Brands, Nike, Rocket Lab and Domino's Pizza are among the stocks on the move.
Reuters · 04/11 16:07
More
Webull provides a variety of real-time ARVN stock news. You can receive the latest news about Arvinas through multiple platforms. This information may help you make smarter investment decisions.
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.